Key facts
- InnotiveDx’s last known valuation is $35.3M (Aug 2025).
- It has raised $12.9M; the latest was Seed Round ($4.6M) in Aug 2025.
- Notable investors include Innovate UK, Texas Medical Center, The University of Liverpool, University of Liverpool Endowment.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for InnotiveDx
- ·The full record, as it builds
Funding rounds
No funding rounds for InnotiveDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InnotiveDx
Operator of a diagnostic company focused on the diagnosis and treatment of urinary tract infections. The company offers an antimicrobial susceptibility test with ground-breaking technology with the potential to transform the diagnosis and treatment of urinary tract infections, thereby offering a cost-effective way to optimize nutrition and overall health.
- Sector
- Healthcare
- HQ
- Bath, United Kingdom
- Founded
- 2019
- Employees
- 29
- Website
- innotivedx.com/
- Ownership
- Privately Held (backing)
InnotiveDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InnotiveDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InnotiveDx in its N-PORT filings yet. We sweep new filings monthly.